
Please try another search
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Daniel N. Bloch | - | 2022 | Director |
Ari S. Kellen | 62 | 2017 | Independent Director & Member of Scientific Advisory Board |
Shawn Langer | - | 2017 | Independent Director & Member of Scientific Advisory Board |
Michael Berelowitz | 81 | 2021 | Special Advisor to the Board |
Gadi Levin | 52 | 2016 | CEO & Chairman |
Daniel Bloch | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review